The authors note that although rare, neurological reactions will likely be encountered with increasing frequency as anti–PD-1 therapy expands to different cancers.
A related editorial discusses this study. Given the role of the immune checkpoint in regulating self-tolerance and autoimmunity, inhibition has been associated with a spectrum of immune related adverse events that are unique to this class of drugs. The horizon of new checkpoint targets continues to expand, and combination therapies are beginning to emerge, therefore neurologists and oncologists need to be aware of the important checkpoints ahead in patient care.